<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00095589</url>
  </required_header>
  <id_info>
    <org_study_id>J0382</org_study_id>
    <secondary_id>U01CA084968</secondary_id>
    <secondary_id>P30CA006973</secondary_id>
    <secondary_id>03-12-30-05</secondary_id>
    <secondary_id>CDR0000401496</secondary_id>
    <nct_id>NCT00095589</nct_id>
    <nct_alias>NCT00185627</nct_alias>
  </id_info>
  <brief_title>Microsatellite Analysis of Urinary Sediment in Detecting Bladder Cancer</brief_title>
  <official_title>Detection of Bladder Cancer by Microsatellite Analysis (MSA) of Urinary Sediment: Multi-Institutional Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: New diagnostic procedures such as microsatellite analysis of sediment in the urine&#xD;
      may improve the ability to detect bladder cancer without invasive procedures.&#xD;
&#xD;
      PURPOSE: Diagnostic trial to study the effectiveness of microsatellite analysis of sediment&#xD;
      in the urine in detecting bladder cancer in healthy participants, participants who have&#xD;
      genitourinary conditions requiring cystoscopy, and patients who have bladder cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
      Primary&#xD;
&#xD;
        -  Compare the sensitivity and specificity of microsatellite analysis (MSA) of urine&#xD;
           sediment with cystoscopy and urine cytology for detecting bladder cancer in participants&#xD;
           undergoing cystoscopy.&#xD;
&#xD;
      Secondary&#xD;
&#xD;
        -  Determine the temporal performance characteristics of MSA in urine sediment from these&#xD;
           participants.&#xD;
&#xD;
        -  Determine which of the 15 individual markers or combination of markers that make up the&#xD;
           MSA test are most predictive of the presence of bladder cancer in these participants.&#xD;
&#xD;
      OUTLINE: This is a single-blind, multicenter, cohort study.&#xD;
&#xD;
      Urine and blood specimens are collected from all participants at baseline. Urine specimens&#xD;
      are examined using microsatellite analysis, urine cytology, and urinalysis. Patients in&#xD;
      groups 2 and 3 also undergo cystoscopy at baseline.&#xD;
&#xD;
      Patients in group 3 undergo cystoscopy, upper tract imaging (e.g., abdominal CT scan),&#xD;
      microsatellite analysis, urine cytology, and urinalysis every 3 months for 2 years in the&#xD;
      absence of progressive disease.&#xD;
&#xD;
      Microsatellite analysis, which identifies loss of heterozygosity using polymerase chain&#xD;
      reaction technique, is conducted for 15 markers: D4S243, D21S1245, FGA, D17S695, D16S476,&#xD;
      D9S171, IFN-A, D20S48, D13S802, D17S654, D16S310, THO1, D9S162, D9S747, and MBP.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 500 participants (100 each for groups 1 and 2 and 300 for group&#xD;
      3) will be accrued for this study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>August 2004</start_date>
  <completion_date type="Actual">June 2009</completion_date>
  <primary_completion_date type="Actual">June 2009</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Cross-Sectional</time_perspective>
  </study_design_info>
  <enrollment type="Actual">125</enrollment>
  <condition>Bladder Cancer</condition>
  <intervention>
    <intervention_type>Genetic</intervention_type>
    <intervention_name>loss of heterozygosity analysis</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Genetic</intervention_type>
    <intervention_name>microarray analysis</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Genetic</intervention_type>
    <intervention_name>microsatellite instability analysis</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>cytology specimen collection procedure</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>laboratory biomarker analysis</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>computed tomography</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>cystoscopy</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Group 1 (healthy volunteers):&#xD;
&#xD;
               -  No prior or concurrent urologic disease or devices&#xD;
&#xD;
               -  No genitourinary (GU) complaints, including urgency or frequency of urination&#xD;
&#xD;
               -  Normal urinalysis and urine cytology&#xD;
&#xD;
               -  Never smoked cigarettes regularly (i.e., ≥ 1 cigarette/day for ≥ 1 year)&#xD;
&#xD;
               -  No suspected exposure to environmental bladder carcinogens for &gt; 1 year,&#xD;
                  including, but not limited to, the following occupations or exposures:&#xD;
&#xD;
                    -  Aluminum industry&#xD;
&#xD;
                    -  Aromatic amines&#xD;
&#xD;
                    -  Coal gasification&#xD;
&#xD;
                    -  Coal tars and pitches&#xD;
&#xD;
                    -  Coke plant&#xD;
&#xD;
                    -  Dye industry&#xD;
&#xD;
                    -  Leather industry&#xD;
&#xD;
                    -  Machinist&#xD;
&#xD;
                    -  Painter&#xD;
&#xD;
                    -  Rubber industry&#xD;
&#xD;
                    -  Truck, bus, or taxi drivers&#xD;
&#xD;
          -  Group 2 (participants with condition(s) that lead to false-positive urinary bladder&#xD;
             cancer screening studies):&#xD;
&#xD;
               -  GU complaints requiring cystoscopy&#xD;
&#xD;
               -  No current GU malignancy&#xD;
&#xD;
               -  At least 1 of the following conditions:&#xD;
&#xD;
                    -  Benign prostatic hypertrophy (International Prostate Symptom Score &gt; 12)&#xD;
&#xD;
                    -  Foreign bodies (stones, stents, or catheters)&#xD;
&#xD;
                    -  Hematuria (gross or microscopic)&#xD;
&#xD;
                    -  GU infection (e.g., prostatitis, urinary tract infection, pyelonephritis,&#xD;
                       urethritis) within the past 3 months and completed treatment&#xD;
&#xD;
                         -  No sign of infection at the time of study participation&#xD;
&#xD;
          -  Group 3 (superficial bladder cancer patients):&#xD;
&#xD;
               -  Histologically confirmed superficial bladder urothelial malignancy&#xD;
&#xD;
                    -  Primary or recurrent disease&#xD;
&#xD;
               -  No nontransitional cell carcinoma of the bladder, upper tract tumors,&#xD;
                  muscle-invasive tumors, or superficial disease for which local therapy is not&#xD;
                  appropriate&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
        Age&#xD;
&#xD;
          -  Over 40&#xD;
&#xD;
        Performance status&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Life expectancy&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Hematopoietic&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Hepatic&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Renal&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
        Other&#xD;
&#xD;
          -  No prior cancer except nonmelanoma dermatologic malignancy&#xD;
&#xD;
               -  Prior bladder cancer allowed for group 3 patients&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
        Biologic therapy&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Chemotherapy&#xD;
&#xD;
          -  No prior chemotherapy&#xD;
&#xD;
               -  Prior intravesical therapy for bladder cancer allowed for group 3 patients&#xD;
&#xD;
        Endocrine therapy&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Radiotherapy&#xD;
&#xD;
          -  No prior radiotherapy&#xD;
&#xD;
        Surgery&#xD;
&#xD;
          -  Not specified&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>120 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mark P. Schoenberg, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Lurleen Wallace Comprehensive Cancer at University of Alabama - Birmingham</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35294</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Stanford Cancer Center</name>
      <address>
        <city>Stanford</city>
        <state>California</state>
        <zip>94305-5824</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Chicago Cancer Research Center</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60637-1470</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21231-2410</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Michigan Comprehensive Cancer Center</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48109-0942</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Siteman Cancer Center at Barnes-Jewish Hospital - Saint Louis</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan-Kettering Cancer Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10021</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>James P. Wilmot Cancer Center at University of Rochester Medical Center</name>
      <address>
        <city>Rochester</city>
        <state>New York</state>
        <zip>14642</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Grand Strand Urology, LLP</name>
      <address>
        <city>Myrtle Beach</city>
        <state>South Carolina</state>
        <zip>29572</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>M. D. Anderson Cancer Center at University of Texas</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030-4009</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dan L. Duncan Cancer Center at Baylor College of Medicine</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Texas Health Science Center at San Antonio</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229-3900</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Edmond Odette Cancer Centre at Sunnybrook</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M4N 3M5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2019</verification_date>
  <study_first_submitted>November 5, 2004</study_first_submitted>
  <study_first_submitted_qc>November 5, 2004</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 8, 2004</study_first_posted>
  <last_update_submitted>February 6, 2019</last_update_submitted>
  <last_update_submitted_qc>February 6, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">February 8, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>bladder cancer</keyword>
  <keyword>stage 0 bladder cancer</keyword>
  <keyword>stage I bladder cancer</keyword>
  <keyword>transitional cell carcinoma of the bladder</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Urinary Bladder Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

